FDA Approves First Gene Therapy for Inherited Deafness

Children who were born unable to hear are now dancing to music and responding to their mother's voice for the first time.

The FDA just approved Otarmeni, the first gene therapy to treat inherited deafness. The groundbreaking treatment targets hearing loss caused by mutations in the OTOF gene, which about 50 American newborns inherit each year.

People with two defective copies of this gene can't produce otoferlin, a protein that inner ear cells need to translate sound vibrations into signals the brain can understand. Without it, the communication line between ear and brain goes silent, causing severe to profound hearing loss from birth.

Otarmeni works by using harmless viruses to deliver working copies of the OTOF gene directly into the ear. Patients receive the treatment just once, and their own cells start producing the missing protein.

The results from the clinical trial were remarkable. Out of 20 participants, 16 showed improved hearing within six months, and one more improved within a year. Some participants improved so much they could hear whispers.

All patients who responded reached a level of hearing that typically doesn't require cochlear implants. These electronic devices bypass damaged parts of the ear but don't perfectly replicate natural hearing and need ongoing maintenance.

The approval process moved remarkably fast, taking less than three years from the first patient dose in 2023. The FDA used its special fast track process because no existing treatments addressed the root cause of OTOF-related hearing loss.

The Ripple Effect

This approval opens doors for treating other genetic causes of hearing loss. Researchers are already testing similar gene therapies in countries like China, building on this success.

Regeneron announced the treatment itself will be free to U.S. patients, though insurance and doctors may still charge administration costs. The therapy is approved for both children and adults who have two defective OTOF gene copies, intact outer hair cells, and haven't previously had a cochlear implant in the ear being treated.

Those with a cochlear implant in one ear can still receive gene therapy in the opposite ear. An international trial continues recruiting children under 18 across the U.S., UK, Spain, Germany, and Japan.

For families who've watched their children grow up in silence, this approval means everything has changed.